Clinical efficacy of abiraterone and enzalutamide metastatic castration sensitive prostate cancer patients who progressed rapidly on docetaxel with a genomic analysis.

Gang Chen,David James VanderWeele,Fatima Karzai,Marijo Bilusic,Munjid Al-Harthy,Philip M. Arlen,Marc Robert Theoret,Inger L. Rosner,Guinevere Chun,Helen Owens,Anna Couvillon,Amy Hankin,Monique Williams,James L. Gulley,William L. Dahut,Ravi A. Madan

Clinical efficacy of abiraterone and enzalutamide metastatic castration sensitive prostate cancer patients who progressed rapidly on docetaxel with a genomic analysis.

2019

Gang Chen
David James VanderWeele
Fatima Karzai
Marijo Bilusic
Munjid Al-Harthy
Philip M. Arlen
Marc Robert Theoret
Inger L. Rosner
Guinevere Chun
Helen Owens
Anna Couvillon
Amy Hankin
Monique Williams
James L. Gulley
William L. Dahut
Ravi A. Madan

e16536Background: Docetaxel has become a standard of care for mCSPC. Enzalutamide and abiraterone have been proven to improve survival in metastatic castration-resistant prostate cancer (mCRPC) pat...

Keywords:

Abiraterone
Oncology
Castration-sensitive prostate cancer
Pathology
Enzalutamide
Internal medicine
Docetaxel
Medicine
standard of care
Prostate cancer
clinical efficacy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations